Immunomedics, Inc.
2020
$21.0B
Why
Gilead acquired Immunomedics for $21 billion to gain control of the Sacituzumab govitecan (Trodelvy) ADC platform, establishing a dominant position in solid tumor oncology.
Impact
The acquisition provided Gilead with a first-mover advantage in the Trop-2 ADC space, generating $1.4 billion in FY2025 sales and establishing a new growth engine for the company.
Outcome
The integration has been highly successful, with Trodelvy expanding into earlier lines of therapy and new indications. The acquisition demonstrates the company's strategy of acquiring late-stage, de-risked assets to fill pipeline gaps.